Syndax Pharmaceuticals, Inc. $SNDX Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 21.2% during the fourth quarter, HoldingsChannel reports. The fund owned 6,230,334 shares of the company’s stock after acquiring an additional 1,091,717 shares during the quarter. Vanguard Group Inc. owned about 0.07% of Syndax Pharmaceuticals worth $130,899,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its position in Syndax Pharmaceuticals by 192.2% in the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock valued at $45,000 after purchasing an additional 1,922 shares during the period. Quantbot Technologies LP acquired a new position in Syndax Pharmaceuticals during the 3rd quarter worth approximately $53,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Syndax Pharmaceuticals by 26.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after buying an additional 893 shares in the last quarter. Lazard Asset Management LLC purchased a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $66,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Syndax Pharmaceuticals by 103.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after buying an additional 4,308 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SNDX. Jefferies Financial Group restated a “buy” rating and issued a $40.00 price target (down from $48.00) on shares of Syndax Pharmaceuticals in a research note on Monday, March 30th. Barclays boosted their price objective on shares of Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Mizuho lowered their price target on Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. Stifel Nicolaus set a $45.00 price objective on Syndax Pharmaceuticals in a research note on Friday, February 27th. Finally, JPMorgan Chase & Co. increased their price target on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the company an “overweight” rating in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.64.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $21.38 on Tuesday. The company has a debt-to-equity ratio of 8.26, a current ratio of 5.47 and a quick ratio of 5.06. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $25.59. The company has a fifty day moving average price of $23.09 and a two-hundred day moving average price of $20.63. The company has a market cap of $1.89 billion, a PE ratio of -7.66 and a beta of 0.41.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Thursday, April 30th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 256.65%. The company had revenue of $64.86 million for the quarter, compared to analysts’ expectations of $69.76 million. During the same period in the prior year, the company earned ($0.98) earnings per share. The firm’s revenue was up 224.3% compared to the same quarter last year. Research analysts expect that Syndax Pharmaceuticals, Inc. will post -1.67 earnings per share for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.